Rekurrens glioblastomában szenvedő betegek kezelése bevacizumab-monoterápiával

INTRODUCTION: The prognosis of patients with recurrent glioblastoma is poor, as the median survival does not exceed 6 months. AIM: The aim of this study was to evaluate the efficacy of bevacizumab monotherapy in patients with recurrent glioblastoma multiforme. METHOD: From April, 2012 to June, 2015, 40 patients with recurrent glioblastoma multiforme were treated with bevacizumab in a dose of 10 mg/kg every 2 weeks. RESULTS: The average progression-free survival was 6.4 months (2-22 months), and the 6-month progression-free survival was 42.5%. The six-month overall survival was 82.5%, which corresponds to those published in the literature. CONCLUSIONS: Bevacizumab monotherapy improves progression-free survival in patients with recurrent glioblastoma multiforme.